The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristicsDavid C. Wheeler, Hiddo J.L. Heerspink, Robert D. Toto et al.|Nephrology Dialysis Transplantation|2020Cited by 189